Results 1 to 10 of about 22,482 (226)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept. [PDF]

PLoS ONE, 2022
PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama, Riko Matsumoto, Shumpei Obata, Osamu Sawada, Yoshitsugu Saishin, Masashi Kakinoki, Tomoko Sawada, Masahito Ohji   +7 more
doaj   +3 more sources

Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report

BMC Ophthalmology
Background To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Nozomu Hashiya, Ichiro Maruko, Yuri Miyaguchi, Ruka Maruko, Taiji Hasegawa, Tomohiro Iida   +5 more
doaj   +2 more sources

Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis

Ophthalmology and Therapy
Introduction This systematic review and meta-analysis aimed to provide an updated evidence base for clinical decision-making by comparing the efficacy and safety of aflibercept 2 mg and ranibizumab in treating retinal vein occlusion (RVO).
Jing Wu, Xiaoning He, Fang Qi, Zhan Zhao, Zhe Xu, Hong Yan   +5 more
doaj   +2 more sources

Aflibercept [PDF]

Clinical Cancer Research, 2013
Abstract Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor (PlGF) agent, has recently been approved by the U.S. Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously ...
Kristen K, Ciombor, Jordan, Berlin, Emily, Chan   +2 more
  +6 more sources

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study

American Journal of Ophthalmology Case Reports
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty, Ashish Sharma, Soumen Mondal, Jay Sheth, Tushar Kanti Sinha, Subhendu Boral, Angshuman Mukherjee, Ranabir Bhattacharya, Ritobroto Maitra   +8 more
doaj   +2 more sources

Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion

Molecules, 2022
Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO).
Lasse Jørgensen Cehofski, Anders Kruse, Alexander Nørgaard Alsing, Benn Falch Sejergaard, Jonas Ellegaard Nielsen, Anders Schlosser, Grith Lykke Sorensen, Jakob Grauslund, Bent Honoré, Henrik Vorum   +9 more
doaj   +1 more source

Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy

Journal of Ophthalmology, 2021
Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy.
Vira S. Ponomarchuk, N.I. Molchaniuk, M. M. Umanets   +2 more
doaj   +1 more source

Transient Vision Loss Associated with Prefilled Aflibercept Syringes

Ophthalmology Science, 2022
Purpose: To describe cases of significant vision loss after intravitreal aflibercept administration using prefilled syringes (PFS) and to study the relationships among syringe design, injection speed, and injection force.
Daniel J. Lee, MD, Brittni A. Scruggs, MD, PhD, Erik Sánchez, PhD, Merina Thomas, MD, Ambar Faridi, MD   +4 more
doaj   +1 more source

Features of aflibercept plus hyperbaric oxygen therapy for diabetic macular edema

Journal of Ophthalmology, 2022
Background: Diabetes mellitus (DM) is a disease characterized by chronic hyperglycemia and a cascade of pathological vascular alterations leading to diabetic retinopathy (DR) and diabetic macular edema (DME).
V. O. Drozdov, V. M. Sakovych
doaj   +1 more source

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]

PLoS ONE, 2015
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin, Fran Milnes   +5 more
doaj   +1 more source